Proteins and Peptides

16 May 2017

ALPHAEON Submits Biologics License Application for DWP-450 Neuromodulator

15 May 2017

Long-term Data Confirm Benefits of Treatment with Strensiq(R) (asfotase alfa) in Adolescents and Adults with Hypophosphatasia (HPP) Through Five Years

11 May 2017

SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection

10 May 2017

Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase

9 May 2017

Molecular Partners’ strategic partner Allergan completed patient recruitment in both abicipar pegol nAMD Phase 3 studies

8 May 2017

Araim Pharmaceuticals’ Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis

5 May 2017

Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery

4 May 2017

Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of Obesity

3 May 2017

NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe

3 May 2017

BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA

3 May 2017

Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection

3 May 2017

Bonti Announces Hot Topics Presentation of Phase 2a Interim Clinical Data at The Aesthetic Meeting 2017

3 May 2017

ImmunGene Regains Antibody-Interferon Fusion Product Candidates from Valor Biotherapeutics

3 May 2017

Stealth BioTherapeutics Initiates Phase 1/2 Trial of SBT-20 in Patients With Early Stage Huntington’s Disease

2 May 2017

Ampio Initiates Pivotal Trial of Ampion

2 May 2017

Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis

2 May 2017

Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex™ Did Not Achieve its Primary Endpoint

28 April 2017

FDA Approves Radius Health’s TYMLOS™ (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture

28 April 2017

Novo Nordisk Receives FDA Approval of Saxenda® (liraglutide) injection 3 mg Label Update Including Long-Term Safety and Efficacy Data from 3-Year Trial

28 April 2017

FDA Approves Brineura™ (cerliponase alfa) for the Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare Pediatric Brain Disorder in Children

28 April 2017

Bonti Announces Inaugural Presentation of Phase 2a Clinical Data for Its Lead Product EB-001

27 April 2017

Ra Pharmaceuticals Initiates Dosing of RA101495 in PNH Patients

26 April 2017

Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

22 April 2017

BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children

22 April 2017

NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

22 April 2017

Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

20 April 2017

First Patient in Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET

20 April 2017

ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema

18 April 2017

Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies

18 April 2017

BioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Report Package: Bispecific Antibodies

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Ustekinumab (Stelara) Biosimilars Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities